Precision Radiation Therapy: Low- to Intermediate-Risk Prostate Cancer
Michael J. Zelefsky, MD, discusses the need for advances in molecular imaging and radiomics and for integrating these techniques with precision radiation ...
Grand Rounds in Urology
Prostate Cancer: Clinical Guidelines, Novel Therapies, and Therapeutic Uncertainty
Earn CME: https://www.naccme.com/program/19-cpc-101-5 This webcast features a presentation by Dr. Atish D. Choudhury that examines the latest clinical ...
ImedexCME
Treatment Approaches for Pancreatic Cancer
This webinar covers standard treatment approaches and clinical trials for pancreatic cancer. This webinar was recorded on January 27, 2016. The presenter is ...
Pancreatic Cancer Action Network
Deciphering Cancer: The Intersection of Epigenetics, Metabolism, and Tumorigenesis
Participating Experts: Kathryn E. Wellen, PhD (UPenn) and Jason Locasale PhD (Duke) ⬇️ Expand “Show More” to view Abstract and Table of Contents Browse ...
Cell Signaling Technology, Inc.
Multimodal Approach to Advanced Prostate Cancer
Martin E. Gleave, MD, FRCSC, FACS, discusses his views on improving advanced prostate cancer treatment approaches. Specifically, he emphasizes methods ...
Grand Rounds in Urology
Early Salvage Radiotherapy for Early Prostate Cancer
The RADICALS-RT and meta-analysis data presented at ESMO 2019 reassure that early salvage may be the best approach vs adjuvant radiotherapy.
OncLiveTV
Chemical Biology Approach to Understanding and Overcoming Resistance of Cancers to Treatments
Stuart L. Schreiber, Harvard University, USA. Introduction by Jan-Erling Bäckvall, member of the Academy's class for chemistry. From: Open Academy Lecture, ...
Vetenskapsakademien
Targeting Cancer Pathways: Tumor Resistance
Participating Experts: Michael Yaffe MD, PhD (MIT), Jeffrey Engleman MD, PhD (Harvard Medical School), and Michael Deininger MD, PhD (U. Utah) ...
Cell Signaling Technology, Inc.
Adjuvant or Salvage RT Post Radical Prostatectomy
Seth R. Blacksburg, MD, MBA, discusses the clinical significance of biochemical failure post-radical prostatectomy (RP). He then reviews the literature ...
Grand Rounds in Urology
Mary Beckerle (University of Utah) Part 1: Adhesion, Signaling and Cancer
Cell-substratum adhesion is mediated by integrins, a family of transmembrane, heterodimeric, extracellular matrix receptors that are concentrated at focal ...
iBiology
Mining the Genome to Understand Epigenetic Abnormalities in Cancer ... - Stephen Baylin
June 29 - July 1, 2015 -- ENCODE 2015: Research Applications and Users Meeting More: http://www.genome.gov/27561910 Full title: Mining the Genome to ...
National Human Genome Research Institute
Novel Approaches for the Detection, Prevention and Treatment of Colorectal Cancer
Raymond DuBois, M.D., Ph.D. is executive director of the Biodesign Institute, Dalton Chair in the School of Health Solutions, and a professor of chemistry and ...
Mayo Clinic
Ambry Genetics: Webinar - Clinical Approaches to Hereditary Cancer Panels
We have a unique “cross-border” conversation with two experienced genetic counselors from the U.S. and Canada, as they review healthcare delivery in their ...
Ambry Genetics
Radiation for Relapsed Prostate Cancer (Indigo Stage) | Prostate Cancer Staging Guide
PCRI's Executive Director, Mark Scholz, MD, describes radiation therapy options for men with relapsed prostate cancer. He explains which options are ...
Prostate Cancer Research Institute
Howard Chang (Stanford, HHMI) 2: LncRNA Function at the RNA Level: Xist
https://www.ibiology.org/genetics-and-gene-regulation/epigenomics-lncrnas In this talk, Dr. Howard Chang describes epigenomic approaches pioneered by his ...
iBiology
Welcome to the Department of Biochemistry and Molecular Genetics
Step inside the Department of Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine and meet the scientists who are ...
NUFeinbergMed
Targeting Cancer Pathways: The Tumor Microenvironment
Rakesh K. Jain, PhD (Harvard Medical School/MGH), and Padmanee Sharma, MD, PhD (MD Anderson Cancer Center) ⬇️ Expand “Show More” to view ...
Cell Signaling Technology, Inc.
2016 WMIF | Epigenetics and Novel Cancer Targets
Moderator: Pat Fortune, PhD, Senior Market Sector Leader, Partners Innovation Robert Copeland, PhD, President of Research and Chief Scientific Officer, ...
World Medical Innovation Forum
Initial Management of Metastatic CRC in 2019
Earn CME for related activities: https://www.naccme.com/oln In this webcast from the '2019 ESMO World Congress on Gastrointestinal Cancer', Dr. Axel Grothey ...
ImedexCME
Triple-Negative Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019
Nancy Lin, MD, discusses advances in research and treatment for patients with triple-negative metastatic breast cancer. Triple-negative breast cancer, which ...
Dana-Farber Cancer Institute
Dr. Thomas Seyfried: Cancer as a Mitochondrial Metabolic Disease
Thomas Seyfried, Ph.D., is a biochemical geneticist, professor of biology at Boston College, and author of the groundbreaking book Cancer as a Metabolic ...
CrossFit®
Engineering T Cells to Conquer Cancer, with Carl June
Cancer Research Institute's Breakthroughs in Cancer Immunotherapy Webinar Series are offered free to the public and feature informative updates from leaders ...
Cancer Research Institute
TRACO 2017 - Ovarian Cancer in the Genomics Era and Immune checkpoints
TRACO 2017 - Ovarian Cancer in the Genomics Era and Immune checkpoints Air date: Monday, September 25, 2017, 4:00:00 PM Category: TRACO Runtime: ...
NIH VideoCast
Dr James Campbell on using genomics approaches to improve radiotherapy treatments
Dr James Campbell, Lead Bioinformatican at the ICR, talks from the floor of the Festival of Genomics 2018 conference. He explains how he uses genomics ...
The Institute of Cancer Research, London
What causes cancer | causes of cancer in men and women
What causes cancer? What are the reasons for cancer? This cancer biology lecture explains the biochemical pathway leading to cause cancer in humen.
Shomu's Biology
Advanced Prostate Cancer - The evolving landscape and targeted therapies
Prof Nicolas Mottet, Prof Piet Ost, Dr Inge van Oort and ProfAmit Bahl discuss the evolving landscape and targeted therapies of advanced prostate cancer at ...
ecancer
Symposium 2014: Targeting RAS Now for Future Cancer Therapy – Introduction
Dr. Frank McCormick, Director of the UCSF Cancer Center and advisor to the NCI RAS Initiative, describes what we do not know about RAS cancers. For more ...
National Cancer Institute
Keynote Presentation: A Comparative Approach to Oncology Drug Development: Integrating
Presented At: Laboratory Animal Sciences Virtual Event 2019 Presented By: Amy LeBlanc, DVM DACVIM - Director, Comparative Oncology Program, Center for ...
LabRoots
Radiotherapy for Oligometastatic Prostate Cancer
Panelists provide insight into the classification of low- versus high-volume metastases (METS) in prostate cancer and implications for use of radiotherapy as ...
OncLiveTV
Advancing Pancreatic Cancer Research at TGen
Headed by Dr. Daniel Von Hoff, TGen's Pancreatic Cancer Research Laboratory focuses on genetic and biochemical approaches to identify diagnostics and ...
tgenvideo
Alfred Wittinghofer (MPI) Part 2: GTPase Reactions and Diseases
https://www.ibiology.org/biochemistry/g-protein/#part-2 In the second part of Dr. Wittinghofer's talk he explains the link between GTPases and disease. Ras is ...
iBiology
Using Genetic Biomarkers for Selection of Targeted Cancer Therapies: PGx Conference 2018
Pharmacogenomics Conference: Genomic Testing to Individualize Drug Therapy 4 Using Genetic Biomarkers for Selection of Targeted Cancer Therapies David ...
PharmacyUMN
The 4 Uses of PSA for Prostate Cancer Care | Prostate Cancer Staging Guide
PCRI Executive Director Mark Scholz, MD, gives a broad overview of how PSA is used for detecting and diagnosing prostate cancer and monitoring prostate ...
Prostate Cancer Research Institute
Treating Patients With Advanced Medullary Thyroid Cancer
In the absence of a curative treatment, maintaining local control remains the goal for patients with advanced medullary thyroid cancer. In this segment, panelists ...
OncLiveTV
Thyroid Cancer: Hypoparathyroidism/Hypocalcemia. Dr. Levine. ThyCa Conference
Hypocalcemia/Hypoparathyroidism: Now That You Have It, What Do You Do? Michael A. Levine, M.D., Endocrinologist, Julie Hunsaker, and Carol Sanders.
ThyCa: Thyroid Cancer Survivors' Association, Inc.
Thyroid Cancer: Thyroid Hormone Replacement. Research, When To Suppress TSH. Dr. Klopper.
Thyroid Cancer: Thyroid Hormone Replacement. Research, When To Suppress TSH. Dr. Klopper. ThyCa Conference. Joshua P. Klopper, M.D., Endocrinologist.
ThyCa: Thyroid Cancer Survivors' Association, Inc.
Prostate Cancer Detection and Survival Rates | Memorial Sloan Kettering
Learn about MSK: https://www.mskcc.org CONNECT WITH MSK Facebook: http://facebook.com/sloankettering Twitter: http://twitter.com/sloan_kettering ...
Memorial Sloan Kettering
TGen & Pancreatic Cancer Research
Pancreatic Cancer is a vicious killer, the fourth leading cause of cancer death in the U.S., claiming a higher percentage of lives than any other form of cancer.
tgenvideo
Debate: Optimal salvage therapy for refractory colon cancer? - TAS102 or Regorafenib
In this presentation from the Great Debates in Gastrointestinal Malignancies 2018 conference, Dr. Andrea Cercek argues in favor of the use of TAS102 or ...
ImedexCME
Kristin Landis-Piwowar - Molecular Diagnostics in Detection, Diagnosis, and Prognosis of Cancer
Watch on LabRoots at: http://labroots.com/user/webinars/details/id/99 Cancer cells have historically been classified by microscopic analysis of blood smears and ...
LabRoots
Imaging of Metastatic Prostate Cancer: Whole Body MRI and Novel PET Techniques
Anwar Padhani, MBBS, FRCP, FRCR, presented “Imaging of Metastatic Prostate Cancer: Whole Body MRI and Novel PET Techniques” at the 6th Symposium on ...
Grand Rounds in Urology
Pancreatic Cancer Q&A
Memorial Sloan-Kettering experts answer questions from the audience about preventing, diagnosing, and treating pancreatic cancer.
Memorial Sloan Kettering
